益盛藥業(002566.SZ):上半年淨利4005.20萬元 經營性現金流改善明顯
格隆匯8月23日丨益盛藥業(002566.SZ)披露2019年半年度報告,報告期內公司實現營業收入5.05億元,同比下降3.47%;歸屬於上市公司股東的淨利潤4005.20萬元,同比增長1.96%;經營活動現金淨流入1.20億元,同比增長86.79%;基本每股收益0.1210元,加權平均淨資產收益率2.14%。
公司的主營業務為中成藥及大健康產品的研發、製造和銷售。公司根據制定的“紮根傳統文化,依靠現代科技,打造完整的人蔘產業鏈”的發展戰略,經過多年的佈局和深耕,公司已從單純的製藥企業成長為貫穿人蔘產業鏈上、中、下游的企業集團,完成了由益盛漢參種植、益盛漢參產業園、益盛藥業、益盛永泰蜂業、益盛漢參化粧品、益盛彩印包裝六大板塊構成的產業佈局,形成了醫藥、中藥飲片、化粧品、保健食品四大事業格局。主要產品包括:振源膠囊、心悦膠囊、生脈注射液、清開靈注射液、消痔靈注射液、西洋參飲片、紅參精提植物飲品、益參妮奧系列化粧品等。
隨着公司產品線的日益豐富,公司針對不同產品根據其不同的消費羣體和消費場景建立了不同的銷售渠道。藥品的銷售主要依託公司多年來建立的自有的營銷團隊通過學術推廣的方式拓展業務;中藥飲片以連鎖藥店銷售為主,同時在益盛漢參公眾號中進行銷售;保健食品、化粧品目前主要通過美容院特許加盟的方式進行銷售。
報告期內,公司加大了核心產品的市場開發和渠道建設力度。拳頭產品振源膠囊和心悦膠囊以確切的療效和過硬的質量進一步得到了廣大患者的認可;同時,公司利用品種優勢,在現有產品中挖掘具有市場競爭力的產品,抓住市場需求,通過學術推廣快速導入市場;拓寬銷售渠道,通過與多家連鎖藥店的合作,促進了中藥飲片的銷售;積極探索“培訓班”和“產品體驗營”等新的銷售模式,實現了產品與服務的融合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.